| Serial Number | 87818001 |
| Word Mark | K KNACK PHARMACEUTICALS YOUR HEALTH PARTNER |
| Filing Date | Friday, March 2, 2018 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Thursday, November 3, 2022 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, July 24, 2018 |
| Description of Mark | The mark consists of the word "KNACK" in a stylized blue font in all uppercase letters, beneath which lies the word "PHARMACEUTICALS" in a second smaller stylized font in gray, to the left of which lies a stylized dark blue ribbon shape oriented horizontally with the legs of the ribbon extending outwards toward the right edge of the ribbon, with a light blue bar bisecting the top part of the ribbon, with a white diamond contained in the middle of the "K", with the two stylized geometric shapes together comprising a stylized letter "K", and below which lies the phrase "YOUR HEALTH PARTNER" in a third light blue stylized font in all uppercase letters. Together the literal elements form the combined phrase "K KNACK PHARMACEUTICALS YOUR HEALTH PARTNER". |
| Goods and Services | Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of epilepsy disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of skin diseases, allergies and rheumatic disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of Alzheimer; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of ophthalmic related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of musculoskeletal related diseases and disorders; Pharmaceutical preparations for the support and promotion of bone strength and health; Pharmaceutical preparations for the treatment of bone disorders and bone diseases; Pharmaceutical preparations for the treatment of toxic effects; Pharmaceutical preparations for use as injectable anesthetics; Pharmaceutical preparations for use as contraceptives; Pharmaceutical preparations for fertility enhancement purposes; Pharmaceutical preparations for use in hormone replacement therapy; Pharmaceutical preparations for the prevention and treatment of hormone disorders and deficiencies; Pharmaceutical preparations for inducing labor and facilitating nursing; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the treatment and prevention of metabolic, endocrine and kidney related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of nausea and vomiting; Pharmaceutical preparations for the prevention and treatment of aids-related disorders and diseases; Pharmaceutical preparations for treatment and prevention of viral and bacterial infections; Pharmaceutical preparations, namely, injectable contraceptives |
| Indication of Colors claimed | The color(s) blue , white and gray is/are claimed as a feature of the mark. |
| Disclaimer with Predetermined Text | "PHARMACEUTICALS" AND "HEALTH" |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 9, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | Sunday, August 1, 2021 |
| First Use In Commerce Date | Sunday, August 1, 2021 |
| Party Name | KNACK PHARMACEUTICALS, INC. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | New York City, NY 10022 |
| Party Name | KNACK PHARMACEUTICALS, INC. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York City, NY 10022 |
| Event Date | Event Description |
| Friday, November 4, 2022 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Thursday, November 3, 2022 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
| Thursday, November 3, 2022 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Thursday, April 21, 2022 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Thursday, April 21, 2022 | FINAL REFUSAL E-MAILED |
| Thursday, April 21, 2022 | SU - FINAL REFUSAL - WRITTEN |
| Monday, March 28, 2022 | ASSIGNED TO EXAMINER |
| Wednesday, March 23, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, March 23, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, March 16, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, March 16, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, November 17, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, November 17, 2021 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Wednesday, November 17, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, November 17, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, September 17, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, September 17, 2021 | NON-FINAL ACTION E-MAILED |
| Friday, September 17, 2021 | SU - NON-FINAL ACTION - WRITTEN |
| Friday, September 17, 2021 | STATEMENT OF USE PROCESSING COMPLETE |
| Friday, September 10, 2021 | USE AMENDMENT FILED |
| Friday, September 10, 2021 | TEAS STATEMENT OF USE RECEIVED |
| Wednesday, March 17, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, March 16, 2021 | SOU EXTENSION 5 GRANTED |
| Tuesday, March 2, 2021 | SOU EXTENSION 5 FILED |
| Tuesday, March 16, 2021 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Tuesday, March 2, 2021 | SOU TEAS EXTENSION RECEIVED |
| Saturday, August 8, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, August 6, 2020 | SOU EXTENSION 4 GRANTED |
| Thursday, August 6, 2020 | SOU EXTENSION 4 FILED |
| Thursday, August 6, 2020 | SOU TEAS EXTENSION RECEIVED |
| Saturday, March 7, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, March 5, 2020 | SOU EXTENSION 3 GRANTED |
| Thursday, March 5, 2020 | SOU EXTENSION 3 FILED |
| Thursday, March 5, 2020 | SOU TEAS EXTENSION RECEIVED |
| Friday, August 30, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, August 28, 2019 | SOU EXTENSION 2 GRANTED |
| Wednesday, August 28, 2019 | SOU EXTENSION 2 FILED |
| Wednesday, August 28, 2019 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, March 6, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, March 4, 2019 | SOU EXTENSION 1 GRANTED |
| Monday, March 4, 2019 | SOU EXTENSION 1 FILED |
| Monday, March 4, 2019 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, September 18, 2018 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, July 24, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 24, 2018 | PUBLISHED FOR OPPOSITION |
| Wednesday, July 4, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Friday, June 15, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, June 15, 2018 | EXAMINER'S AMENDMENT ENTERED |
| Friday, June 15, 2018 | ASSIGNED TO LIE |
| Thursday, June 14, 2018 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, June 14, 2018 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, June 14, 2018 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, June 13, 2018 | ASSIGNED TO EXAMINER |
| Saturday, March 10, 2018 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Friday, March 9, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, March 6, 2018 | NEW APPLICATION ENTERED |